Crovalimab is currently in clinical development for patients with paroxysmal nocturnal
haemoglobinuria (PNH). PNH is a rare, acquired, life-threatening disease of the blood. The disease
is characterised by destruction of red blood cells, blood clots, and impaired bone marrow function.
It is a blood condition where blood cells are prone to be attacked by part of the body’s immune
system.
Crovalimab for treatment of paroxysmal nocturnal haemoglobinuria
Crovalimab is currently in clinical development for patients with paroxysmal nocturnal haemoglobinuria (PNH).
Interventions:
Crovalimab
Indications:
Paroxysmal nocturnal haemoglobinuria (PNH)
Therapeutic Areas:
Haematology
Year:
2022